A method has been devised for treating the urethral syndrome by cryosurgery using a special applicator. The results in the first 35 cases are presented and compared with a similar group of women treated by urethral dilatation. The cryosurgical method has proved to be successful and free of complications. The study is being continued.
Introduction
The treatment of women complaining of frequency and dysuria constitutes a large proportion of the workload of any urological department. The syndrome, variously called the urethral syndrome or urethrotrigonitis, is defined by us as consisting of intermittent attacks of frequency by day and night with dysuria and a sterile urine containing no pus cells and with normal intravenous urography. It has been treated in the past by urethral dilatation, diathermy to the bladder neck, diathermy of the urethral mucosa in strips and other methods, all of which have met with varying success. Many patients have not been completely cured and some have been made worse. Urethral dilatation, for instance, can cause severe dysuria, haematuria, temporary incontinence and later urethral stenosis.
A pilot study has been carried out on a technique for treating the urethral syndrome in women by cryosurgery using a special applicator.
Methods
All patients are investigated by cystoscopy to confirm the diagnosis of the urethral syndrome and to exclude the presence of stone, tumour, interstitial cystitis, tuberculosis and other organic disease. Cystoscopy usually reveals inflammation of the trigone and internal urethral meatus often with polypi and occasionally cystitis cystica on the trigone near the ureteric orifices.
The patient is placed in the cystoscopy position and the vulva cleansed with chlorhexidine (Hibitane) or cetrimide (Cetavlon). The urethra is lubricated with lignocaine and Chlorhexidine Gel. A general anaesthetic is usually given, but the procedure can and has been carried out successfully under the local anaesthetic effect of the lignocaine and Chlorhexidine Gel alone.
Provided no other lesion is found, the urethrotrigonitis is treated by cryosurgery using a special perspex applicator ( Figure 1 ). This consists of a 9 mm diameter perspex tube with a long handle which allows for easy introduction into the urethra. The front portion of the tube is a solid tongue of perspex, and in the remaining two-thirds adjoining the handle there is a 4 mm diameter groove on one side into which the cryoprobe is inserted (for the liquid nitrous oxide cryoprobe, the smallest active end supplied by Keymed).
The applicator is inserted into the urethra and the bladder emptied. The cryoprobe is then inserted into the applicator, the metal probe thus being in contact only with the anterior surface of the urethra. A strip of urethra is then frozen to a depth of 2-3 mm (taking 10-15 seconds), the temperature of the probe being approximately -75°C ( Figure 2 ). The applicator is then turned through 180°and a posterior strip of urethra frozen. In order to prevent the Figure 2 . Applicator, with cryoprobe, inserted into urethra development of strictures, it is important to preserve normal strips of mucosa laterally; the applicator is designed to achieve this.
It is our belief that minor gynaecological and anal conditions contribute to the presence of urethrotrigonitis. Thus following cystoscopy the cervix is examined and if erosion is present a smear is taken and the cervical erosion also treated by cryosurgery. Any other minor gynaecological condition is also noted, for example, anterior and posterior prolapse, vaginal discharge, retroversion of the uterus, or even an hysterectomy scar. Anal fissures or haemorrhoids are treated at the same time if possible.
Patients treated by this method have been interviewed during follow up using a proforma, and have been compared retrospectively with a randomly selected group of patients who underwent urethral dilatation with a dilator 1.4 cm in diameter (II Hegar).
Results
During the last nine months, 35 patients aged 19-71 years have undergone cryosurgery for treatment of the urethral syndrome. Twenty-nine had cystoscopic evidence ofurethrotrigonitis, and associated pathology was found in 18-13 with cervical erosions, 2 with haemorrhoids, 1 with anal fissure, and 2 with previous hysterectomy. Follow up has been from 2-36 weeks with an average of 12 weeks. The comparison group of 35 patients who underwent dilatation had an average age of 45 years. The incidence of associated pathology was similar to the cryosurgery group and patients were followed up for an average of 15 weeks.
The two groups were compared using the information provided on the proformas (Table 1 ). In the cryosurgery group no patients had a worsening of symptoms; the one patient in whom there was no improvement developed an E. coliurinary tract infection postoperatively. Of the 8 patients in the dilatation group who showed no improvement, 2 suffered postoperative urethral haemorrhage, one needing a blood transfusion. The 4 patients whose symptoms worsened complained of frequency and/or dysuria.
The 35 women who underwent cryosurgery were asked to give their opinion ofthe procedure and responded as follows: excellent 15, good 18, worthless 1, don't know 1. Thirty-four said they would have the procedure again should the symptoms recur. 
Discussion
In the past urethral dilatation has, on the whole, been successful and patients grateful. However, it can cause considerable frequency and dysuria which may persist making the patient's condition worse overall, and can also cause urethral haemorrhage. In many cases dilatation has to be repeated.
Cryosurgery seems to cause much less discomfort and no increase in frequency and dysuria nor urethral haemorrhage. The features of cryosurgery important in this context are that the tissue destroyed by freezing is painless, and that it heals by epithelization from the edges with apparently little or no risk of either primary or secondary haemorrhage.
It seems to be a feature of urethrotrigonitis that the symptoms come in attacks at irregular intervals, and the length of follow up of cases in the present series is as yet short. However, many of the patients treated early in the series have now remained symptom free for several months-much longer than ever before. In order to followup patients over a longer period and to assess the results in a greater number of cases, the study is being continued.
